Refractory to standard therapy
Showing 1 - 25 of >10,000
Immune-related Adverse Events Refractory to Standard Therapy and
Recruiting
- Immune-related Adverse Event
- Extracorporeal photopheresis
- Other immunosuppressive or immunomodulatory drugs
-
Munich, GermanyLMU Klinikum Hauttumorzentrum
Jan 17, 2023
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Relapsed/Refractory Follicular Lymphoma Trial in Nashville (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Axicabtagene Ciloleucel
- +8 more
-
Denver, Colorado
- +6 more
Dec 2, 2022
REnal reCOVery After ECMO for Cardiogenic Shock (RECOVECMO)
Recruiting
- Cardiogenic Shock
- +2 more
- standard of care
-
Pessac, FranceBordeaux University Hospital
Mar 27, 2023
Pediatric Oncology Trial in Worldwide (Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell
Active, not recruiting
- Pediatric Oncology
- Regorafenib (BAY73-4506)
- +2 more
-
Lyon, France
- +11 more
Jan 16, 2023
Solid Tumor Trial in Duarte (RNR inhibitor COH29, laboratory biomarker analysis, pharmacological study)
Suspended
- Unspecified Adult Solid Tumor, Protocol Specific
- RNR inhibitor COH29
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Semi-automated Segmentation Methods of SSTR PET for Dosimetry
Not yet recruiting
- Refractory Meningioma
- To evaluate the SUVmean (Standard Uptake Value) as a predictive factor of the tumor absorbed dose compared to the SUVmax
- (no location specified)
Sep 8, 2022
Acute Leukemia, Recurrent Leukemia, Refractory Leukemia Trial in Columbus (Best Practice, Bright White Light Therapy, Survey
Recruiting
- Acute Leukemia
- +2 more
- Best Practice
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 14, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Prostate Cancer, mCRPC Trial in Seoul (Lu-177-DGUL, Ga-68-NGUL)
Recruiting
- Prostate Cancer
- mCRPC
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 22, 2022
Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma Trial in United States (STP705)
Active, not recruiting
- Hepatocellular Carcinoma
- +2 more
-
Scottsdale, Arizona
- +4 more
Dec 13, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
Acute Myeloid Leukemia Trial in Pittsburgh (mitoxantrone + etoposide + gemtuzumab ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- mitoxantrone + etoposide + gemtuzumab ozogamicin
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 9, 2022
High-Risk Neuroblastoma Trial in Krakow (Chemoimmunotherapy (Dinutuximab beta in combination with chemo))
Recruiting
- High-Risk Neuroblastoma
- Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
-
Krakow, Malopolska, PolandUniversity Children Hospital
Mar 8, 2022
ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, No-Reflow Phenomenon Trial in Tomsk (Standard therapy,
Active, not recruiting
- ST Elevation Myocardial Infarction
- +2 more
- Standard therapy
- +3 more
-
Tomsk, Tomsk Region, Russian FederationCardiology Research Institute, Tomsk NRMC
Oct 31, 2022
Head Neck Cancer, Metastatic Cancer, Oligoprogressive Trial in Montréal (Standard arm, Experimental arm)
Recruiting
- Head and Neck Cancer
- +2 more
- Standard arm
- Experimental arm
-
Montréal, Quebec, CanadaCentre Hospitalier de l'Université de Montréal
Mar 6, 2022
Hematological Malignancies, CMV Infection Trial in Belgium (CMV-specific T cells, Standard anti-viral therapy)
Completed
- Hematological Malignancies
- CMV Infection
- CMV-specific T cells
- Standard anti-viral therapy
-
Gent, Oost-Vlaanderen, Belgium
- +7 more
Dec 19, 2022
Eosinophilic Granulomatosis With Polyangiitis Trial in Tulsa, Norfolk (Depemokimab, Mepolizumab, Placebo matching mepolizumab)
Not yet recruiting
- Eosinophilic Granulomatosis With Polyangiitis
- Depemokimab
- +3 more
-
Tulsa, Oklahoma
- +1 more
Jul 19, 2022
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available Trial
Completed
- Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
-
Houston, TexasM.D. Anderson Cancer Center
Aug 22, 2022
Advanced Cancers, Solid Tumors Trial in Houston (Pazopanib, Everolimus)
Active, not recruiting
- Advanced Cancers
- Solid Tumors
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 16, 2022
Patients With Advanced Refractory Solid Tumors
Not yet recruiting
- Feasibility
- +3 more
- Targeted therapy
- (no location specified)
Dec 14, 2021
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (Best Practice, Chart
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Best Practice
- +6 more
- (no location specified)
Jul 12, 2022